Variable | FAR-H/DM (n = 1116) | FAR-L/DM (n = 1189) | FAR-H/Non-DM (n = 1265) | FAR-L/Non-DM (n = 1728) | P value |
---|---|---|---|---|---|
FAR | 0.099 ± 0.021 | 0.067 ± 0.009 | 0.098 ± 0.021 | 0.066 ± 0.008 |  < 0.001 |
Baseline characteristics | |||||
 Age, years | 60.86 ± 10.03 | 58.20 ± 9.70 | 59.54 ± 10.75 | 56.01 ± 10.21 |  < 0.001 |
 Male, n (%) | 779 (69.8) | 957 (80.5) | 937 (74.1) | 1,146 (83.7) |  < 0.001 |
 BMI, kg/m2 | 26.20 ± 3.22 | 26.37 ± 3.01 | 25.54 ± 3.09 | 25.63 ± 3.18 |  < 0.001 |
 DM, n (%) | 1116 (48.4) | 1189 (51.6) | – | – |  < 0.001 |
 Hypertension, n (%) | 784 (70.3) | 807 (67.9) | 788 (62.3) | 1007 (58.3) |  < 0.001 |
 Dyslipidemia, n (%) | 826 (74.0) | 868 (73.0) | 818 (64.7) | 1145 (66.3) |  < 0.001 |
 Smoking history, n (%) | 624 (55.9) | 697 (58.6) | 732 (57.9) | 1054 (61.0) | 0.053 |
 Family history of CAD, n (%) | 230 (20.6) | 276 (23.2) | 282 (22.3) | 434 (25.1) | 0.040 |
 Previous MI, n (%) | 236 (21.1) | 258 (21.7) | 198 (15.7) | 344 (19.9) | 0.001 |
 Previous PCI, n (%) | 274 (24.6) | 341 (28.7) | 220 (17.4) | 394 (22.8) |  < 0.001 |
 Previous stroke, n (%) | 162 (14.5) | 133 (11.2) | 120 (9.5) | 141 (8.2) |  < 0.001 |
Previous PAD, n (%) | 41 (3.7) | 43 (3.6) | 24 (1.9) | 42 (2.4) | 0.014 |
 Clinical presentation, n (%) |  |  |  |  |  < 0.001 |
  CCS | 443 (39.7) | 583 (49.0) | 438 (34.6) | 794 (45.9) |  |
  ACS | 673 (60.3) | 606 (51.0) | 827 (65.4) | 934 (54.1) |  |
Laboratory tests | |||||
 FIB, g/L | 4.05 ± 0.77 | 2.91 ± 0.42 | 3.99 ± 0.78 | 2.84 ± 0.39 |  < 0.001 |
 Albumin, g/L | 41.22 ± 3.75 | 43.52 ± 3.57 | 41.12 ± 3.67 | 43.34 ± 3.66 |  < 0.001 |
 FBG, mmol/L | 7.28 ± 2.43 | 7.22 ± 2.40 | 5.07 ± 0.56 | 5.08 ± 0.58 |  < 0.001 |
 HbA1c, % | 7.67 ± 1.40 | 7.36 ± 1.21 | 5.93 ± 0.31 | 5.86 ± 0.35 |  < 0.001 |
 TG, mmol/L | 1.85 ± 1.13 | 1.97 ± 1.40 | 1.68 ± 0.85 | 1.72 ± 0.93 |  < 0.001 |
 TC, mmol/L | 4.22 ± 1.13 | 4.14 ± 1.09 | 4.19 ± 1.03 | 4.14 ± 1.09 | 0.173 |
 HDL-C, mmol/L | 0.98 ± 0.26 | 1.02 ± 0.26 | 1.01 ± 0.27 | 1.06 ± 0.29 |  < 0.001 |
 LDL-C, mmol/L | 2.54 ± 0.94 | 2.41 ± 0.89 | 2.52 ± 0.88 | 2.45 ± 0.93 | 0.002 |
 hs-CRP, mg/L | 5.08 ± 4.48 | 1.71 ± 2.03 | 4.82 ± 4.38 | 1.42 ± 1.73 |  < 0.001 |
 Creatinine, μmol/L | 76.44 ± 19.39 | 74.83 ± 15.27 | 75.71 ± 16.55 | 74.70 ± 13.24 | 0.019 |
 eGFR, mL/min/1.73 m2 | 88.16 ± 17.12 | 92.39 ± 14.89 | 90.03 ± 15.15 | 94.52 ± 13.09 |  < 0.001 |
 LVEF, % | 62.12 ± 7.45 | 63.22 ± 6.85 | 62.90 ± 7.50 | 64.19 ± 6.40 |  < 0.001 |
Medications at admission, n (%) | |||||
 Aspirin, n (%) | 1104 (98.9) | 1177 (99.0) | 1247 (98.6) | 1717 (99.4) | 0.199 |
 Clopidogrel, n (%) | 1114 (99.8) | 1185 (99.7) | 1264 (99.9) | 1723 (99.7) | 0.517 |
 β-blocker, n (%) | 1108 (91.2) | 1115 (93.8) | 1146 (90.6) | 1550 (89.7) | 0.002 |
 CCB, n (%) | 566 (50.7) | 583 (49.0) | 704 (55.7) | 960 (55.6) |  < 0.001 |
 Statins, n (%) | 1069 (95.8) | 1140 (95.9) | 1226 (96.9) | 1677 (97.0) | 0.157 |
 Nitrate, n (%) | 1088 (97.5) | 1153 (97.0) | 1232 (97.4) | 1689 (97.7) | 0.638 |
 Insulin, n (%) | 319 (28.6) | 294 (24.7) | – | – |  < 0.001 |
Coronary procedural information | |||||
 LM/three-vessel disease, n (%) | 604 (54.1) | 568 (47.8) | 525 (41.5) | 685 (39.6) |  < 0.001 |
 Chronic total occlusion, n (%) | 66 (5.9) | 86 (7.2) | 98 (7.7) | 127 (7.3) | 0.338 |
 Target vessel territory, n (%) |  |  |  |  | 0.001 |
  LAD | 471 (42.2) | 540 (45.4) | 623 (49.2) | 878 (50.8) |  |
  LCX | 232 (20.8) | 211 (17.7) | 207 (16.4) | 305 (17.7) |  |
  RCA | 396 (35.5) | 426 (35.8) | 415 (32.8) | 520 (30.1) |  |
 Number of stents | 1.79 ± 0.86 | 1.77 ± 0.86 | 1.76 ± 0.94 | 1.75 ± 0.89 | 0.677 |
 SYNTAX score | 12.76 ± 8.47 | 11.77 ± 8.27 | 12.14 ± 8.22 | 10.92 ± 7.41 |  < 0.001 |
 Complete revascularization, n (%) | 1106 (99.1) | 1185 (99.7) | 1256 (99.3) | 1721 (99.6) | 0.209 |
 DES implantation, n (%) | 1099 (98.5) | 1175 (98.8) | 1253 (99.1) | 1699 (98.3) | 0.331 |